F8 and hemophilia: When delivered to hemophilia A mice at a vector dose of 1 × 1011 vg/kg, AAV-HCB-HSQ-LCO achieved persistent fVIII activity of approximately 0.4 IU/mL, which was greater than that achieved with AAV-HLP-V3co (Figure 6D).